BioSpace News Archive

Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2021.

Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, reported financial results for the three and nine months ended September 30, 2021.

Lantern Pharma, a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform the cost, pace, and timeline of oncology drug discovery and development, provided a business update and reported financial results for the third quarter ended September 30, 2021.

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 171,300 shares of Karyopharm’s common stock to 15 newly-hired employees, with a grant date of October 29, 2021.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 11,000 shares of Akebia’s common stock on October 29, 2021, as inducements material to each such employee’s entering into employment with Akebia.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that it will release third quarter 2021 financial results after the market closes on Monday, November 8, 2021.

Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act target date for ciltacabtagene autoleucel to February 28, 2022.

Hologic, Inc. announced the Company’s financial results for the fiscal fourth quarter ended September 25, 2021.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 133,000 shares of the company’s common stock to two new employees.